Yifan Pharmaceutical Co (002019) Fair Value & Analysis
Healthcare · CN · Market cap 12.1B CNY
Fair value as of: Jul 21, 2026
From 15 valuation models · updated 20 days ago
Share price +5.1% over the past month.
A solid business, but screening 33% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (¥8.95). The favourable scenario is already priced in.
- Solid but not exceptional quality (56/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (¥4.96 to ¥8.95) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 21, 2026.
How to read this chart
60‑month range ¥9.17 – ¥21.72 · fair‑value band ¥4.96 – ¥8.95 · the ¥10.34 price screens above the ¥6.89 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 21, 2026.
Analysis
Yifan Pharmaceutical Co (002019) currently trades at ¥10.34, while our model-based Fair Value estimate is ¥6.89, implying the stock looks roughly 33.4% overvalued today. The Quality Score stands at 56/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Yifan Pharmaceutical Co generated revenue of 5.1B CNY at a net margin of 7.0%. Revenue declined 5.4% year over year. It earns a return on equity of 3.8%. Net debt stands at 1.3B CNY. Fundamentals as of Jul 21, 2026
Our scenario range runs from ¥4.96 (bear case) to ¥8.95 (bull case); at ¥10.34, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 37% below its 52-week high and 6% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -25% fair-value upside, at -33%, 002019 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 15 models by family
Widest divergence: Growth Earnings (¥6.89) versus DCF Models (¥3.88). Highest evidence: Residual Income (76).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 21, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 54 · Market factors (momentum, volatility) 31
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Yifan Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products, vitamins, and polymer materials in China, South Korea, the Philippines, Vietnam, Italy, Thailand, and internationally.
Full company description
Yifan Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products, vitamins, and polymer materials in China, South Korea, the Philippines, Vietnam, Italy, Thailand, and internationally. It offers pharmaceutical products, such as biopharmaceuticals, chemical drugs, and traditional Chinese medicines; vitamin products, including vitamin B5 and provitamin B5; and active pharmaceutical ingredients. The company was formerly known as Yifan Xinfu Pharmaceutical Co., Ltd. and changed its name to Yifan Pharmaceutical Co., Ltd. in October 2016. Yifan Pharmaceutical Co., Ltd. was founded in 2000 and is headquartered in Hangzhou, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Yifan Pharmaceutical Co reported revenue of ¥5.1B in FY2025 versus ¥4.4B in FY2021, a compound +3.9%/yr. Reported net income was ¥402M in FY2025, compounding +9.6%/yr from FY2021.
002019 screens 33% overvalued. Compare with Eli Lilly and Company →
Peer Group
Drug Manufacturers - General · 76 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - General median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Jul 21, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,182 | $396.77 | -66% |
| Johnson & Johnson, JNJ | $257.59 | $169.04 | -34% |
| AbbVie Inc ABBV | $254.49 | $67.72 | -73% |
| Roche Holding 1RO | €392.80 | €226.68 | -42% |
| Merck & Co MRK | €108.08 | €121.54 | +12% |
| Novartis AG NVSN | 2,742 MXN | 2,379 MXN | -13% |
| AstraZeneca PLC AZN | $171.61 | $129.54 | -25% |
| Novo Nordisk A/S NOVOB | kr 329.90 | kr 409.46 | +24% |
| Amgen Inc AMGN | $363.39 | $252.02 | -31% |
| Sanofi SNYN | 770.00 MXN | 1,251 MXN | +63% |
Compare Yifan Pharmaceutical Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Yifan Pharmaceutical Co (002019) overvalued or undervalued?
What is the fair value of 002019?
What is the quality score of 002019?
What is the revenue of Yifan Pharmaceutical Co (002019)?
What is the net profit margin of 002019?
Does Yifan Pharmaceutical Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Yifan Pharmaceutical Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.